References
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023;61:2200879.
- Bisserier M, Pradhan N, Hadri L. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med 2020;21:163–179.
- Bartolome S, Hoeper MM, Klepetko W. Advanced pulmonary arterial hypertension: mechanical support and lung transplantation. Eur Respir Rev 2017;26:170089.
- Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39:4175–4181.
- Westerhof BE, Saouti N, van der Laarse WJ, et al. Treatment strategies for the right heart in pulmonary hypertension. Cardiovasc Res 2017;113:1465-1473.
- Ten Dijke P; Arthur HM. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857–869.
- Ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79–89.
- Liang H, Zhang C, Ban T, et al. A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 2012;44:2152–2160.
- Goumans MJ; Ten Dijke P. TGF-β signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol 2018;10:a022210.
- Goumans MJ, Zwijsen A, Ten Dijke P, Bailly S. Bone morphogenetic proteins in vascular homeostasis and disease. Cold Spring Harb Perspect Biol 2018;10:a031989.
- Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019;53:1801900.
- Inampudi C, Tedford RJ, Hemnes AR, et al. Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. Cardiovasc Diagn Ther 2020;10:1659–1674.
- Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
- Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.
- Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:1898–1907.
- McGregor PC, Boosalis V, Aragam J. Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: a case report. SAGE Open Med Case Rep 2021;9:2050313X21994031.
- Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 2021;384:1204–1215.
- Joshi SR, Liu J, Bloom T, et al. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep 2022;12:7803.
- Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023;388:1478–1490.
- Chin KM, Gaine SP, Gerges P, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J 2024;64:2401325.
- Kopeć G, Skride A, Ereminiene E, et al. Emerging therapies and new directions in the treatment of pulmonary arterial hypertension. Kardiol Pol 2025;83:18–26.
- Hoeper MM, Pausch C, Grünig E, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J 2022;59:2102024.